180 related articles for article (PubMed ID: 11708186)
1. Amprenavir (Agenerase).
Res Initiat Treat Action; 2000 Mar; 6(1):32-3. PubMed ID: 11708186
[No Abstract] [Full Text] [Related]
2. New protease inhibitor.
Vazquez E
Posit Aware; 1999; 10(3):24. PubMed ID: 11366764
[TBL] [Abstract][Full Text] [Related]
3. Nelfinavir (Viracept).
Res Initiat Treat Action; 2000 Mar; 6(1):30-1. PubMed ID: 11708185
[No Abstract] [Full Text] [Related]
4. Indinavir (Crixivan).
Res Initiat Treat Action; 2000 Mar; 6(1):28-9. PubMed ID: 11708184
[No Abstract] [Full Text] [Related]
5. Ritonavir (Norvir).
Res Initiat Treat Action; 2000 Mar; 6(1):26-7. PubMed ID: 11708183
[No Abstract] [Full Text] [Related]
6. Saquinavir (Fortovase or Invirase).
Res Initiat Treat Action; 2000 Mar; 6(1):24-5. PubMed ID: 11708182
[No Abstract] [Full Text] [Related]
7. Agenerase approved by FDA.
Gaylord G
Posit Living; 1999 May; 8(4):6. PubMed ID: 12492061
[No Abstract] [Full Text] [Related]
8. Amping amprenavir with ritonavir.
TreatmentUpdate; 2001; 12(12):10. PubMed ID: 11570075
[No Abstract] [Full Text] [Related]
9. Drug interactions. Amprenavir with low-dose ritonavir.
TreatmentUpdate; 2006; 18(3):9-10. PubMed ID: 17211921
[No Abstract] [Full Text] [Related]
10. Amprenavir (AGENERASE) oral solution: warning for some patients.
AIDS Treat News; 2000 May; (342):3. PubMed ID: 12870457
[TBL] [Abstract][Full Text] [Related]
11. New treatment options.
Fornataro K; Jefferys R
Body Posit; 1999 Jun; 12(6):11-2. PubMed ID: 11367013
[TBL] [Abstract][Full Text] [Related]
12. HIV protease mutations associated with amprenavir resistance during salvage therapy: importance of I54M.
Murphy MD; Marousek GI; Chou S
J Clin Virol; 2004 May; 30(1):62-7. PubMed ID: 15072756
[TBL] [Abstract][Full Text] [Related]
13. Amprenavir (Agenerase).
Simmons P
Res Initiat Treat Action; 1999 Jul; 5(3):7-10. PubMed ID: 11366726
[TBL] [Abstract][Full Text] [Related]
14. [Resistance to protease inhibitors].
Clotet B; Martínez-Picado J; Arrizabalaga J; Ruiz L
Enferm Infecc Microbiol Clin; 2001 Feb; 19(Monografico):34-41. PubMed ID: 11428058
[No Abstract] [Full Text] [Related]
15. Human immunodeficiency virus type 1 hypersusceptibility to amprenavir in vitro can be associated with virus load response to treatment in vivo.
Zachary KC; Hanna GJ; D'Aquila RT
Clin Infect Dis; 2001 Dec; 33(12):2075-7. PubMed ID: 11700580
[TBL] [Abstract][Full Text] [Related]
16. Amprenavir may be less cross-resistant with other PIs.
Murphy MJ
HIV Clin; 1999; 11(5):1, 7. PubMed ID: 11810849
[No Abstract] [Full Text] [Related]
17. Response to "key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients".
Picchio G; De Meyer S; de Béthune MP
AIDS; 2008 Jan; 22(1):165-7. PubMed ID: 18090413
[No Abstract] [Full Text] [Related]
18. Study: new drug doesn't display cross-resistance.
AIDS Alert; 1999 Jul; 14(7):77. PubMed ID: 11366418
[TBL] [Abstract][Full Text] [Related]
19. Amprenavir: a new HIV protease inhibitor.
Med Lett Drugs Ther; 1999 Jul; 41(1057):64-6. PubMed ID: 10436772
[No Abstract] [Full Text] [Related]
20. Four posters add to our knowledge of Lexiva.
Proj Inf Perspect; 2008 Dec; (47):7-8. PubMed ID: 19227558
[No Abstract] [Full Text] [Related]
[Next] [New Search]
